Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Psychiatr. Sep 22, 2013; 3(3): 62-64
Published online Sep 22, 2013. doi: 10.5498/wjp.v3.i3.62
Published online Sep 22, 2013. doi: 10.5498/wjp.v3.i3.62
Acetylcholinesterase inhibitors in cognitive impairment in Huntington’s disease: A brief review
Joe John Vattakatuchery, Renjith Kurien, 5 Boroughs Partnership NHS Foundation Trust, Warrington WA28WA, United Kingdom
Author contributions: Both authors contributed equally to this article.
Correspondence to: Joe John Vattakatuchery, MBBS, MRCPsych, Consultant Psychiatrist, 5 Boroughs Partnership NHS Foundation Trust, Hollins Park House, Hollins Lane, Warrington WA28WA, United Kingdom. joejohn@doctors.net.uk
Telephone: +44-19-25666647 Fax: +44-19-25666645
Received: June 29, 2013
Revised: August 24, 2013
Accepted: September 3, 2013
Published online: September 22, 2013
Processing time: 144 Days and 12.4 Hours
Revised: August 24, 2013
Accepted: September 3, 2013
Published online: September 22, 2013
Processing time: 144 Days and 12.4 Hours
Core Tip
Core tip: The evidence for Acetylcholinesterase inhibitors in the treatment of cognitive decline and dementia associated with Huntington’s disease is reviewed in this article. Six articles were identified that investigated the role of Acetylcholinesterase inhibitors for treatment of cognitive deficits in Huntington’s disease (HD). We concluded that there is limited evidence for the use of Acetylcholinesterase inhibitors for cognitive impairment in HD.